Abstract
The practice of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) in COVID-19 hypertensive patients is still an ope......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
